Lv1
40 积分 2025-08-07 加入
P3.12D.01 A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
1年前
已关闭
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer
1年前
已完结
皖公网安备34019202002308
